Efficacy of photodynamic therapy against doxorubicin-resistant murine tumors

Cancer Lett. 1995 Jul 13;93(2):255-9. doi: 10.1016/0304-3835(95)03818-h.


Photodynamic therapy (PDT) is a relatively new cancer treatment modality that employs light excitation of a photosensitizer to yield cytotoxic oxygen-related species. In the present study we explored whether PDT would have therapeutic effect against doxorubicin-resistant murine tumors. We compared the efficacy of PDT with aluminium disulphonated phthalocyanine (A1S2Pc) and laser light on the doxorubicin-sensitive murine tumors, B16 melanoma (B16), L1210 leukemia (L1210), P388 lymphoma (P388) and the corresponding doxorubicin-resistant lines (B16/Dx, L1210/Dx and P388/Dx). Mice bearing L1210-L1210/Dx, P388-P388/Dx and B16-B16/Dx, were treated with 5 mg/kg of A1S2Pc and laser light (100 mW/cm2 x 10 min of exposure) or with doxorubicin (10 or 12 mg/kg i.v.). The results show that PDT is active versus all tumors while doxorubicin is effective only against the three sensitive tumor lines (L1210, P388 and B16). These observations suggest that PDT might be a beneficial alternative treatment for drug-resistant tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Doxorubicin / therapeutic use*
  • Drug Resistance
  • Indoles / therapeutic use*
  • Leukemia L1210 / drug therapy
  • Lymphoma / drug therapy
  • Melanoma, Experimental / drug therapy
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Neoplasms, Experimental / drug therapy*
  • Organometallic Compounds / therapeutic use*
  • Photochemotherapy*


  • Indoles
  • Organometallic Compounds
  • aluminum phthalocyanine disulfonate
  • Doxorubicin